NCT06135844

Brief Summary

The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at P25-P50 for early_phase_1

Timeline
Completed

Started Apr 2022

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 8, 2022

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

October 30, 2023

Completed
19 days until next milestone

First Posted

Study publicly available on registry

November 18, 2023

Completed
12 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2023

Completed
Last Updated

November 18, 2023

Status Verified

November 1, 2023

Enrollment Period

1.6 years

First QC Date

October 30, 2023

Last Update Submit

November 13, 2023

Conditions

Keywords

VirusHSV-1Herpes Simplex 1Herpes Simplex Labialis

Outcome Measures

Primary Outcomes (1)

  • Duration of HSV-1 Lesion

    1\. Is there a statistically significant difference in the duration of the HSV-1 lesion in individuals who use Purell hand sanitizer on their lesion versus those who are in the control group using medical grade mineral oil? The duration will be determined when the crust of the lesion has fallen off and the lesion is fully healed. Once healed, the participant will be required to return to the clinic for a concluding photograph taken by the research assistant and return the daily journal.

    1-14 days

Secondary Outcomes (3)

  • Level of Pain during Treatment

    1-14 days

  • Level of Discomfort during Treatment

    1-14 days

  • Size of Lesion during Treatment

    1-14 days

Study Arms (2)

Treatment Group (Hand Sanitizer)

EXPERIMENTAL

Participants with an early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom), with the visible manifestation of a lesion will be invited to participate in the study. Participants will apply a large drop of hand sanitizer in an unmarked container to a Q-tip and will hold the Q-tip on the lesion for 10 seconds. The hand sanitizer will be administered every waking hour in the same manner.

Drug: Purell Hand Sanitizer

Control Group (Medical Grade Mineral Oil)

PLACEBO COMPARATOR

Participants with an early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom), with the visible manifestation of a lesion will be invited to participate in the study. Participants will apply a large drop of Medical Grade Mineral Oil in an unmarked container to a Q-tip and will hold the Q-tip on the HSV-1 lesion for 10 seconds. The medical grade mineral oil will be administered every waking hour in the same manner.

Drug: Medical Grade Mineral Oil

Interventions

Active ingredient. Ethyl alcohol 70%

Also known as: Hand Sanitizer
Treatment Group (Hand Sanitizer)

Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.

Also known as: Mineral Oil
Control Group (Medical Grade Mineral Oil)

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • For the purpose of this study participants must be:
  • in the early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom)
  • have a visible manifestation of a lesion
  • be 18 years or older
  • capable of following daily treatment instructions
  • willing to complete a daily journal
  • willing to come to the clinic twice for records and pictures during the14 days that the lesion is present or until participant is free of lesion.

You may not qualify if:

  • For the purpose of this study participants cannot:
  • be immunocompromised
  • be pregnant
  • have taken any antiviral medication within the last two weeks
  • have used any creams in the last ten days.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Idaho State University

Pocatello, Idaho, 83209, United States

RECRUITING

Cotton Creek Dental

St. George, Utah, 84780, United States

RECRUITING

Utah Tech University

St. George, Utah, 84790, United States

RECRUITING

Related Publications (2)

  • Angewandte V. As a biocidal active substance, ethanol is indispensable for hygienic hand disinfection. Zentralsterilisation. 2020; 28(6):354-359. Our study has never been investigated by researchers. This is a pilot study exploring the effectiveness of ethyl alcohol on HSV-1 lesions. Therefore all research studies pertain to the virucidal effects of 70% ethyl alcohol.

    BACKGROUND
  • Sauerbrei A. Bactericidal and virucidal activity of ethanol and povidone-iodine. Microbiologyopen. 2020 Sep;9(9):e1097. doi: 10.1002/mbo3.1097. Epub 2020 Jun 22.

    PMID: 32567807BACKGROUND

Related Links

MeSH Terms

Conditions

Virus DiseasesHerpes Labialis

Interventions

Hand SanitizersMineral Oil

Condition Hierarchy (Ancestors)

InfectionsHerpes SimplexHerpesviridae InfectionsDNA Virus InfectionsSkin Diseases, ViralLip DiseasesMouth DiseasesStomatognathic DiseasesSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Anti-Infective Agents, LocalAnti-Infective AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and UsesDisinfectantsSpecialty Uses of ChemicalsPetrolatumHydrocarbonsOrganic Chemicals

Study Officials

  • Leciel Bono, MS

    Idaho State University

    STUDY CHAIR

Central Study Contacts

Leciel Bono, MS

CONTACT

Amanda Gibbs, MS candidate

CONTACT

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will be divided into two groups: Control Group (mineral oil) and the Treatment Group (hand sanitizer). Each group will be asked to apply the product to the HSV-1 lesion. Sample Inclusion Criteria: For the purpose of this study participants must be in the early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom), with the visible manifestation of a lesion, 18 years or older, capable of following daily treatment instructions, willing to complete a daily journal and willing to come to either clinic twice for photos during the duration of the lesion (day 3 and when the lesion has healed or the crust has fallen off the lesion).
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor, Graduate Program Director/Interim Dept. Chair

Study Record Dates

First Submitted

October 30, 2023

First Posted

November 18, 2023

Study Start

April 8, 2022

Primary Completion

November 30, 2023

Study Completion

November 30, 2023

Last Updated

November 18, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations